Table 2. Clinical presentations and identified germline mutations of each individual.

Individual	Sex	Age (y)	Age at onset (y)	Histology	Tumor stage	Mutant gene	MutCount/ Sequencing depth	Amino acid change and origin	SRA accession numbers	Hom/Het
I:1	F	83	82	Lung adenocarcinoma	Ⅳ	WRN	345/738	N1370Tfs*23, Mat	SRR1563024	Het
						DICER1	113/255	N1112D, Mat		Het
						ELAC2	135/255	Y83C, Mat		Het
Ⅱ:1	F	54	52	Endometrial cancer	Ⅱ	WRN	396/888	N1370Tfs*23, Mat	SRR1563027	Het
						ELAC2	132/255	Y83C, Mat		Het
Ⅱ:2	F	52	50	Lung adenocarcinoma	Ⅳ	WRN	304/723	N1370Tfs*23, Mat	SRR1563036	Het
						DICER1	107/208	N1112D, Mat		Het
						ELAC2	140/255	Y83C, Mat		Het
Ⅱ:3	F	50		No evidence of cancer		ELAC2	134/255	Y83C, Mat	SRR1563037	Het
Ⅱ:4	F	47		No evidence of cancer		ELAC2	131/255	Y83C, Mat	SRR1563039	Het
Ⅱ:5	F	45		No evidence of cancer		WRN	58/148	N1370Tfs*23, Mat	SRR1563041	Het
						ELAC2	46/85	Y83C, Mat		Het

F, female; Mat, maternal family; Hom/Het, homozygote/heterozygote; SRA, Sequence Read Archive.